SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

Preclinical consolidation: MSI firm Protea buys CRO vivoPharm

08-Apr-2015 - Molecular imaging company Protea Biosciences has acquired CRO vivoPharm in the latest instance of consolidation in the preclinical sector.

Exclusive interview

Rise in outsourcing to lead to further CMO consolidation, DPx CEO says

18-Mar-2015 - The CMO (contract manufacturing organization) industry is ripe for consolidation as the rise in outsourcing continues and clients look to simplify their supply chains, DPx CEO James Mullen told Outsourcing-Pharma.com...

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

05-Mar-2015 - Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US...

Exclusive interview

It's not the size... CRO Simbec-Orion on why it can compete with Quintiles

05-Feb-2015 - Being a drug developer not just a service provider differentiates Simbec-Orion from the Big CROs according to CEO Ronald Openshaw, whose firm signed two strategic partnerships last week.

Covance's LabCorp distraction will drive opportunities for CRL, says analyst

23-Jan-2015 - Investment firm William Blair has upgraded preclinical CRO Charles River Laboratories to ‘outperform’ based on strong toxicology demand and the pending acquisition of Covance.

INTERACTIVE POLL

Consolidation among small CROs could drive up prices, says analyst

21-Jan-2015 - Competition among small CROs kept prices steady in 2014 despite higher sponsor R&D spending and greater outsourcing penetration, according to a Citi Research survey.

One-stop-shop CMOs could fall into pharma's over-capacity curse, say experts

16-Jan-2015 - CMO consolidation is resurrecting the ‘all-under-one-roof’ manufacturing model, but will firms fall into the same inefficiency pitfalls that drove pharma to outsource in the first place?

Shareholder nod for Medtronic and Covidien's $43bn 'strategic' merger

07-Jan-2015 - The $43bn (€36bn) megamerger between Medtronic and Covidien is one step closer after shareholders voted to approval the deal yesterday.

Quintiles will continue to grow through acquisitions, says S&P

10-Dec-2014 - Quintiles has been upgraded to stable by ratings agency Standard & Poor after a second stock offering and the consolidation of debt through a $300m securitisation facility.

CMO use to grow despite Big Biopharma's in-house spend, say experts

02-Dec-2014 - Third-party manufacturers anxious about Big Biopharma investments and downbeat industry reports can relax as experts concur “it’s a time of growth for biopharmaceutical outsourcing.”

Recipharm adds French plant and drug delivery tech in strategic deal with Flamel

27-Nov-2014 - Recipharm will acquire a facility and add technologies including spray granulation and spray coating as part of a “truly strategic” collaboration with France-based Flamel Technologies. 

German CMO looks to grow US biz through rise in SMEs and virtual pharma

24-Nov-2014 - Rottendorf is looking to break from being “the best kept secret in the CMO world” by targeting the thousands of virtual and SME pharma firms in the US, according to its CEO....

Dispatches from FT Global Pharmaceutical and Biotechnology conference, London

Quintiles CEO: Change in R&D paradigm must come from Pharma's boardrooms

19-Nov-2014 - Vertical integration is inhibiting pharma R&D innovation, according to Quintiles CEO Tom Pike who says executives must be involved in selecting CROs.

INFOGRAPHIC

PPD and inVentiv: Are the last privately-owned Big CROs ready to go public?

13-Nov-2014 - Soon PPD and inVentiv will be the only privately-owned top eight CROs, which prompted us to weigh up the firms in the event that either goes public in the near...

ERT moves into trial management software with eClinical Insights acquisition

11-Nov-2014 - Patient safety and efficacy endpoint data collector ERT has acquired eClinical Insights (eCI), a provider of cloud-based clinical trials management software, for an undisclosed sum.  

Analyst says Covance execs are smart to back Lab Corp deal

04-Nov-2014 - Lab Corp will buy Covance for $6.1bn in a surprise deal that follows another quarter in which early phase gains were offset by underperformance in central labs.

news from cphi

CDMO strategic deals 'the new standard,' say Catalent and DPx, but big and small pharma demands differ

16-Oct-2014 - Strategic relationships with contract manufacturers are becoming the standard, but big and small pharma demands differ considerably according to the two largest CDMOs, DPx and Catalent.

PPD increases stake in small molecule discovery company X-Chem citing Big Pharma relationships

29-Sep-2014 - CRO PPD has exercised its option to acquire the remaining minority ownership interest of X-Chem for an undisclosed sum. X-Chem will continue to operate as a small molecule discovery company...

Opinion

Public or private: Where Catalent goes, will other CMOs follow?

18-Sep-2014 - Following the recent IPO from Catalent, has private equity called time on the CDMO industry? Outsourcing-pharma’s Dan Stanton thinks it has for now.

Dispatches from ChemOutsourcing

CMO consolidation: Do biopharma partners see any benefits?

17-Sep-2014 - As contract manufacturers continue to consolidate , some in the industry are questioning whether the resulting companies have the ability to offer the same services as the former individual companies. 

News focus

Public CROs are sign of booming market, not PE apathy say financial advisors

15-Sep-2014 - Experts have predicted more CROs will go public as Private Equity looks to get a return on its investments, but such shifts are indicative of a booming market rather than...

PRA Health Sciences evaluates IPO option again with SEC filing

10-Sep-2014 - A little more than a year after it was acquired by private equity company KKR (Kohlberg Kravis Roberts & Co.) for $1.4bn , newly rebranded PRA Health Sciences is looking to...

Investors losing interest in CROS? Have your say in our poll

Quintiles' investor day: Has Private Equity called time on the CRO sector?

08-Sep-2014 - An under-attended investor day at Quintiles, the world’s largest CRO, is indicative of waning interest in the clinical sector according to a William Blair analyst.

UPDATE

Shire takes over SCM Pharma, after manufacturing license is revoked

14-Aug-2014 - Shire has entered SCM Pharma into administration and acquired its assets after the CDMO lost its cGMP license at a UK sterile plant.

Injectables outsourcing growing despite pharma M&A, says AMRI

06-Aug-2014 - Big Pharma is still reliant on CMOs despite talk of returning in-house, says AMRI, which has launched into the top ten manufacturers in the US injectables sector following its recent...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...